These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Other||2004-002050-66||INTERRUPCIÓN DEL TRATAMIENTO EN NIÑOS CON INFECCIÓN CRÓNICA POR VIH||not-yet-due|
|Ongoing||2005-004433-18||Plasma pharmacokinetic study of once versus twice daily abacavir as part of combination antiretroviral therapy in children with HIV-1 infection aged 3 months to <36 months||not-yet-due|
|Listed as ongoing, but also has a completion date and reported results||2009-012947-40||BREATHER (PENTA 16): Short-Cycle Therapy (SCT) (5 days on/2 days off) in young people with chronic HIV||2016-09-13||bad-data|
|Listed as ongoing, but also has a completion date and reported results||2009-013648-35||A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-dailyversus once-daily Iopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral the...||2014-06-06||bad-data|
|Not reported||2011-001515-31||EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM IN INFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL OR CONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTER RANDOMISED PHASE III TRIAL||2014-12-17||due-trials|
|Not reported||2011-001521-25||: NEOMERO 2: FARMACOCINÉTICA Y SEGURIDAD DE MEROPENEM EN NIÑOS DE EDADES HASTA 90 DÍAS (INCLUSIVE) CON MENINGITIS PROBABLE O CONFIRMADA: ENSAYO MULTICÉNTRICO EUROPEO DE FASE I-II||2014-12-12||due-trials|
|Other||2013-001476-37||SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) -||not-yet-due|
|Other||2014-002632-14||A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART||not-yet-due|
|Ongoing||2015-000203-89||Multi-centre, randomised, open label, phase IIb study to compare the efficacy, safety and pharmacokinetics (PK) of an optimised dosing to a standard dosing regimen of vancomycin in neonates and infant...||not-yet-due|